Kindstar Globalgene Technology (HKG:9960) First Half 2024 Results
Key Financial Results
- Revenue: CN¥473.3m (down 3.9% from 1H 2023).
- Net income: CN¥11.9m (down 73% from 1H 2023).
- Profit margin: 2.5% (down from 8.9% in 1H 2023). The decrease in margin was primarily driven by lower revenue.
- EPS: CN¥0.013 (down from CN¥0.046 in 1H 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Kindstar Globalgene Technology Earnings Insights
Looking ahead, revenue is forecast to grow 32% p.a. on average during the next 2 years, compared to a 11% growth forecast for the Healthcare industry in Hong Kong.
Performance of the Hong Kong Healthcare industry.
The company's shares are down 4.3% from a week ago.
Risk Analysis
Be aware that Kindstar Globalgene Technology is showing 2 warning signs in our investment analysis and 1 of those is a bit concerning...
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.